23 September 2026 · MHRA
Meropenem leaflet errors prompt Class 4 medicines defect notification
Doctors & NHSMedical businessesRegulation & claims
B. Braun Melsungen AG has notified the MHRA of errors in the patient information leaflet included in some batches of Meropenem 1000 mg powder and solvent for solution for infusion. The MHRA has issued a Class 4 Medicines Defect Notification, reference EL(26)A/39.
Why it matters
The notification concerns the accuracy of information supplied with a medicine, making it relevant to medicines governance and patient communication.
Protect your practice
Summary for general information only — not legal, clinical or insurance advice.